

# Heidi Taipale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3967005/publications.pdf>

Version: 2024-02-01

155  
papers

4,437  
citations

136885

32  
h-index

138417

58  
g-index

155  
all docs

155  
docs citations

155  
times ranked

4389  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29,823 Patients With Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 686.	6.0	460
2	20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). <i>World Psychiatry</i> , 2020, 19, 61-68.	4.8	232
3	Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 499.	6.0	191
4	Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 197, 274-280.	1.1	179
5	Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. <i>World Psychiatry</i> , 2022, 21, 248-271.	4.8	156
6	From prescription drug purchases to drug use periods – a second generation method (PRE2DUP). <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 21.	1.5	137
7	20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2018, 175, 765-773.	4.0	134
8	Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia – A Nationwide Study With 20-Year Follow-up. <i>Schizophrenia Bulletin</i> , 2018, 44, 1381-1387.	2.3	117
9	Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. <i>JAMA Psychiatry</i> , 2018, 75, 347.	6.0	116
10	The clinical course of schizophrenia in women and men – a nation-wide cohort study. <i>NPJ Schizophrenia</i> , 2020, 6, 12.	2.0	93
11	Mortality in schizophrenia: 30-year nationwide follow-up study. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 492-499.	2.2	87
12	Impact of High Risk Drug Use on Hospitalization and Mortality in Older People with and without Alzheimer's Disease: A National Population Cohort Study. <i>PLoS ONE</i> , 2014, 9, e83224.	1.1	78
13	Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study. <i>BMJ Open</i> , 2016, 6, e012100.	0.8	75
14	No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1802-1808.	0.2	69
15	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104608.	2.9	67
16	Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 749-761.	3.7	66
17	High prevalence of psychotropic drug use among persons with and without Alzheimer's disease in Finnish nationwide cohort. <i>European Neuropsychopharmacology</i> , 2014, 24, 1729-1737.	0.3	64
18	Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. <i>Clinical Epidemiology</i> , 2016, Volume 8, 363-371.	1.5	61

#	ARTICLE	IF	CITATIONS
19	Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. <i>Lancet Psychiatry</i> , 2021, 8, 883-891.	3.7	50
20	Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study. <i>Maturitas</i> , 2017, 98, 7-13.	1.0	47
21	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials. <i>JAMA Psychiatry</i> , 2022, 79, 210.	6.0	47
22	Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. <i>Cmaj</i> , 2017, 189, E519-E529.	0.9	46
23	Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland. <i>International Clinical Psychopharmacology</i> , 2014, 29, 216-223.	0.9	44
24	Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research – the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study. <i>Clinical Epidemiology</i> , 2013, 5, 277.	1.5	43
25	Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer's disease – exposure-matched cohort study. <i>BMC Geriatrics</i> , 2016, 16, 204.	1.1	43
26	Hospital-treated mental and behavioral disorders and risk of Alzheimer's disease: A nationwide nested case-control study. <i>European Psychiatry</i> , 2017, 43, 92-98.	0.1	42
27	Use of Antiepileptic Drugs and Dementia Risk – an Analysis of Finnish Health Register and German Health Insurance Data. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1123-1129.	1.3	41
28	Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia. <i>NPJ Schizophrenia</i> , 2021, 7, 1.	2.0	40
29	Employment among people with schizophrenia or bipolar disorder: A population-based study using nationwide registers. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 61-71.	2.2	39
30	Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. <i>Lancet Psychiatry</i> , 2017, 4, 547-553.	3.7	39
31	Research Priorities for Optimizing Geriatric Pharmacotherapy: An International Consensus. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 193-199.	1.2	35
32	Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021, 47, 23-30.	2.3	35
33	Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study. <i>Pain</i> , 2017, 158, 252-260.	2.0	34
34	Antipsychotic Use and Risk of Hospitalization or Death Due to Pneumonia in Persons With and Those Without Alzheimer Disease. <i>Chest</i> , 2016, 150, 1233-1241.	0.4	33
35	The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case-control study. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 91-100.	2.2	33
36	Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1611-1620.	2.3	33

#	ARTICLE	IF	CITATIONS
37	Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer's disease. <i>International Clinical Psychopharmacology</i> , 2015, 30, 202-208.	0.9	32
38	Drug exposure in register-based research—An expert-opinion based evaluation of methods. <i>PLoS ONE</i> , 2017, 12, e0184070.	1.1	31
39	Hospital admissions, outpatient visits and healthcare costs of community-dwellers with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 955-963.	0.4	30
40	Head or brain injuries and Alzheimer's disease: A nested case-control register study. <i>Alzheimer's and Dementia</i> , 2017, 13, 1371-1379.	0.4	30
41	In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. <i>British Journal of Psychiatry</i> , 2020, 217, 498-505.	1.7	30
42	The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 809-818.	1.2	27
43	Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, e107-e115.	1.3	27
44	Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 87.e15-87.e21.	1.2	26
45	Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease. <i>European Neuropsychopharmacology</i> , 2018, 28, 1260-1269.	0.3	26
46	Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. <i>Psychological Medicine</i> , 2020, 50, 1356-1367.	2.7	26
47	Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 166-175.	2.3	26
48	Incidence of antidepressant use in community-dwelling persons with and without Alzheimer's disease: 13-year follow-up. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 94-101.	1.3	25
49	Morbidity and mortality in schizophrenia with comorbid substance use disorders. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 42-49.	2.2	25
50	Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. <i>Lancet Psychiatry</i> , 2022, 9, 271-279.	3.7	25
51	Long-term use of antipsychotics among community-dwelling persons with Alzheimer's disease: A nationwide register-based study. <i>European Neuropsychopharmacology</i> , 2015, 25, 1706-1713.	0.3	24
52	Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 107-118.	1.2	24
53	Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease—a nested case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1135-1142.	1.9	24
54	Comparison of dispensed medications and forensic toxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1112-1122.	0.9	24

#	ARTICLE	IF	CITATIONS
55	Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 583-590.	1.3	24
56	Burden for Parents of Patients With Schizophrenia—A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls. <i>Schizophrenia Bulletin</i> , 2019, 45, 794-803.	2.3	24
57	Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland. <i>JAMA Network Open</i> , 2020, 3, e2019029.	2.8	24
58	Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. <i>Schizophrenia Bulletin</i> , 2021, 47, 1621-1630.	2.3	24
59	Differences in analgesic use in community-dwelling persons with and without Alzheimer's disease. <i>European Journal of Pain</i> , 2017, 21, 658-667.	1.4	23
60	Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e257-e263.	1.1	23
61	Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons. <i>British Journal of Psychiatry</i> , 2015, 207, 444-449.	1.7	22
62	Initiation and long-term use of benzodiazepines and Z-drugs in bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 634-646.	1.1	22
63	Adherence to psychotropic medication in completed suicide in Sweden 2006–2013: a forensic-toxicological matched case-control study. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1421-1430.	0.8	22
64	Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer's disease in a Finnish nationwide cohort. <i>Scandinavian Journal of Public Health</i> , 2016, 44, 150-158.	1.2	21
65	Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study. <i>Pain</i> , 2019, 160, 417-423.	2.0	20
66	Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study. <i>Journal of Affective Disorders</i> , 2020, 277, 885-892.	2.0	20
67	Antipsychotic Polypharmacy among a Nationwide Sample of Community-Dwelling Persons with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 1223-1228.	1.2	19
68	Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 655-663.	2.3	19
69	Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 435-440.	0.7	18
70	The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 595-602.	1.3	16
71	Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nationwide cohort of 125,556 patients. <i>Addiction</i> , 2021, 116, 1990-1998.	1.7	16
72	Registry-based studies: What they can tell us, and what they cannot. <i>European Neuropsychopharmacology</i> , 2021, 45, 35-37.	0.3	16

#	ARTICLE	IF	CITATIONS
73	Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences. <i>Nordic Journal of Psychiatry</i> , 2021, 75, 315-322.	0.7	15
74	Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. <i>Lancet Psychiatry</i> , 2022, 9, 353-362.	3.7	15
75	Drug use in persons with and without Alzheimer's disease aged 90 years or more. <i>Age and Ageing</i> , 2016, 45, 900-904.	0.7	14
76	A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer's Disease in the US and Finland. <i>Drugs and Aging</i> , 2017, 34, 55-65.	1.3	14
77	Molecular signaling pathways underlying schizophrenia. <i>Schizophrenia Research</i> , 2021, 232, 33-41.	1.1	14
78	Use of benzodiazepines and related drugs is associated with a risk of stroke among persons with Alzheimer's disease. <i>International Clinical Psychopharmacology</i> , 2017, 32, 135-141.	0.9	13
79	Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 711-718.	0.8	13
80	Use of antimentia drugs and risk of pneumonia in older persons with Alzheimer's disease. <i>Annals of Medicine</i> , 2017, 49, 230-239.	1.5	12
81	Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 387-395.	1.2	11
82	Risk and risk factors for disability pension among patients with treatment resistant depression – a matched cohort study. <i>BMC Psychiatry</i> , 2020, 20, 232.	1.1	11
83	Incidence of antidepressant use among community dwellers with and without Parkinson's disease – a nationwide cohort study. <i>BMC Geriatrics</i> , 2021, 21, 202.	1.1	11
84	Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 127-132.	1.2	10
85	Sedative load and salivary secretion and xerostomia in community-dwelling older people. <i>Gerodontology</i> , 2016, 33, 177-184.	0.8	10
86	Risk Factors for Initiation of Potentially Inappropriate Medications in Community-Dwelling Older Adults with and without Alzheimer's Disease. <i>Drugs and Aging</i> , 2017, 34, 67-77.	1.3	10
87	Is Alzheimer's Disease Associated with Previous Opioid Use?. <i>Pain Medicine</i> , 2018, 19, 2115-2121.	0.9	10
88	Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer's disease. <i>Annals of Medicine</i> , 2019, 51, 294-305.	1.5	10
89	Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease. <i>Neurology</i> , 2020, 94, e2099-e2108.	1.5	10
90	Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder. <i>Schizophrenia Bulletin</i> , 2021, 47, 1099-1107.	2.3	10

#	ARTICLE	IF	CITATIONS
91	Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients. <i>Schizophrenia Research</i> , 2021, 228, 367-372.	1.1	10
92	Concomitant Use of Acetylcholine Esterase Inhibitors and Urinary Antispasmodics Among Finnish Community-Dwelling Persons With Alzheimer Disease. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 722-727.	0.7	9
93	Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer's Disease: A Nested Case-Control Study. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 119-128.	1.2	9
94	Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer's Disease: A Cohort Study in Finland. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 2184-2192.	1.7	9
95	Month and Season of Birth as a Risk Factor for Alzheimer's Disease: A Nationwide Nested Case-control Study. <i>Journal of Preventive Medicine and Public Health</i> , 2016, 49, 134-138.	0.7	9
96	Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 774-784.	2.3	9
97	Use of Cholinesterase Inhibitors Increases Initiation of Urinary Anticholinergics in Persons with Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1510-1512.	1.3	8
98	Incidence of head injury and traumatic brain injury among people with Alzheimer's disease. <i>Journal of Epidemiology and Community Health</i> , 2019, 73, 451-454.	2.0	8
99	Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 417-425.	0.8	8
100	Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia. <i>Medical Care</i> , 2020, 58, 763-769.	1.1	8
101	Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study. <i>Journal of Affective Disorders</i> , 2022, 308, 236-242.	2.0	8
102	Associations across spatial patterns of disease incidences, socio-demographics, and land use in Finland 1991-2010. <i>Scandinavian Journal of Public Health</i> , 2015, 43, 356-363.	1.2	7
103	Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 59.	3.0	7
104	Causes of death in a nationwide cohort of community-dwellers with Alzheimer's disease. <i>BMC Geriatrics</i> , 2020, 20, 441.	1.1	7
105	Initiation of antidepressant use among refugee and Swedish-born youth after diagnosis of a common mental disorder: findings from the REMAIN study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 463-474.	1.6	7
106	Concomitant use of benzodiazepines and opioids in community-dwelling older people with or without Alzheimer's disease: A nationwide register-based study in Finland. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 280-288.	1.3	6
107	Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1243-1251.	1.2	6
108	Risk Factors for Disability Pension among Young Adults Diagnosed with Attention-deficit Hyperactivity Disorder (ADHD) in Adulthood. <i>Journal of Attention Disorders</i> , 2022, 26, 723-734.	1.5	6



#	ARTICLE	IF	CITATIONS
109	Labour market marginalisation in young adults diagnosed with attention-deficit hyperactivity disorder (ADHD): a population-based longitudinal cohort study in Sweden. <i>Psychological Medicine</i> , 2023, 53, 1224-1232.	2.7	6
110	Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics. <i>Clinical and Translational Science</i> , 2020, 13, 1170-1177.	1.5	6
111	The effect of comprehensive geriatric assessment on anticholinergic exposure assessed by four ranked anticholinergic lists. <i>Archives of Gerontology and Geriatrics</i> , 2017, 68, 195-201.	1.4	5
112	Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1488-1494.e3.	1.2	5
113	Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer's disease: a nested case-control study. <i>Osteoporosis International</i> , 2019, 30, 1481-1489.	1.3	5
114	Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 487-494.	2.2	5
115	Does Recent Hospitalization Increase Antipsychotic Initiation Among Community Dwellers With Alzheimer's Disease?. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1543-1547.e3.	1.2	5
116	Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer's disease in 2005-2011. <i>PLoS ONE</i> , 2017, 12, e0173450.	1.1	5
117	Antipsychotic Use and Risk of Stroke Among Community-Dwelling People With Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 1059-1065.e4.	1.2	5
118	Real-world effectiveness of pharmacological treatments of opioid use disorder in a national cohort. <i>Addiction</i> , 2022, 117, 1683-1691.	1.7	5
119	Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 751-758.	1.2	4
120	Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease. <i>International Journal of Cardiology</i> , 2020, 300, 221-225.	0.8	4
121	Coronary Revascularization and Postoperative Outcomes in People With and Without Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1524-1530.	1.7	4
122	Association of recent hospitalisation with antidepressant initiation among community dwellers with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1075-1084.	1.3	4
123	Persistence of antidepressant use among refugee youth with common mental disorder. <i>Journal of Affective Disorders</i> , 2021, 294, 831-837.	2.0	4
124	Antidepressant use among immigrants with depressive disorder living in Finland: A register-based study. <i>Journal of Affective Disorders</i> , 2022, 299, 528-535.	2.0	4
125	Prescription opioids among older adults: ten years of data across five countries. <i>BMC Geriatrics</i> , 2022, 22, 429.	1.1	4
126	Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer's Disease. <i>Drugs and Aging</i> , 2015, 32, 937-945.	1.3	3



#	ARTICLE	IF	CITATIONS
127	Sedative load, carious teeth and infection in the periodontium among community-dwelling older people. <i>Gerodontology</i> , 2017, 34, 13-23.	0.8	3
128	Screening approach for identifying candidate drugs and drug-drug interactions related to hip fracture risk in persons with Alzheimer disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 875-889.	0.9	3
129	Systemic Estrogen Use and Discontinuation After Alzheimer's Disease Diagnosis in Finland 2005-2012: A Nationwide Exposure-Matched Cohort Study. <i>Drugs and Aging</i> , 2018, 35, 985-992.	1.3	3
130	Commentary on Robert Whitaker's viewpoint. <i>Psychological Medicine</i> , 2020, 50, 2653-2654.	2.7	3
131	Trajectories of antidepressant use and characteristics associated with trajectory groups among young refugees and their Swedish-born peers with diagnosed common mental disorders—findings from the REMAIN study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2022, 57, 305-317.	1.6	3
132	Switches and early discontinuations of antidepressant medication in young adults with depression. <i>Journal of Affective Disorders</i> , 2021, 295, 1474-1481.	2.0	3
133	Trajectories of labour market marginalisation among young adults with newly diagnosed attention-deficit/hyperactivity disorder (ADHD). <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e67.	1.8	3
134	Allopurinol, dipyridamole and calcium channel blockers in the treatment of bipolar disorder – A nationwide cohort study. <i>Journal of Affective Disorders</i> , 2022, 313, 43-48.	2.0	3
135	Detection of medications associated with Alzheimer's disease using ensemble methods and cooperative game theory. <i>International Journal of Medical Informatics</i> , 2020, 141, 104142.	1.6	2
136	Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring. <i>Scientific Reports</i> , 2020, 10, 1219.	1.6	2
137	Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer's Disease. <i>Clinical Epidemiology</i> , 2021, Volume 13, 295-307.	1.5	2
138	Changes in the use of diabetes drugs among community-dwelling people with Alzheimer's disease. <i>BMC Geriatrics</i> , 2021, 21, 701.	1.1	2
139	Occupational Branch and Labor Market Marginalization among Young Employees with Adult Onset of Attention Deficit Hyperactivity Disorder—A Population-Based Matched Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7254.	1.2	2
140	Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 494-497.	0.7	1
141	Risk of Treatment Failure: Response to Ghosh and Noble. <i>American Journal of Psychiatry</i> , 2018, 175, 1267-1267.	4.0	1
142	Hospitalization after Oral Antibiotic Initiation in Finnish Community Dwellers with and without Alzheimer's Disease: Retrospective Register-Based Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 437-445.	1.2	1
143	Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer's Disease. <i>Drugs and Aging</i> , 2020, 37, 193-203.	1.3	1
144	Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study. <i>Psychological Medicine</i> , 2023, 53, 833-843.	2.7	1

#	ARTICLE	IF	CITATIONS
145	Incidence of Bisphosphonate Use in Relation to Diagnosis of Alzheimer's Disease in Community-Dwelling Persons. <i>Journal of the American Geriatrics Society</i> , 2016, 64, e48-9.	1.3	0
146	Reply to: Use of Antiepileptic Drugs and Dementia Risk—an Analysis of Finnish Health Register and German Health Insurance Data. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1853-1854.	1.3	0
147	Risk of Treatment Failure: Response to Czobor and Volavka. <i>American Journal of Psychiatry</i> , 2018, 175, 909-909.	4.0	0
148	S210. COMPARATIVE EFFECTIVENESS OF ANTIPSYCHOTICS FOR RISK OF ATTEMPTED OR COMPLETED SUICIDE AMONG PERSONS WITH SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S118-S119.	2.3	0
149	T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER. <i>Schizophrenia Bulletin</i> , 2020, 46, S311-S312.	2.3	0
150	Rejoinder to rejoinder to commentary. <i>Psychological Medicine</i> , 2020, 50, 2812-2813.	2.7	0
151	Automated multi-dose dispensing in persons with and without Alzheimer's disease—impacts on pharmacotherapy. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 513-521.	0.8	0
152	Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder. <i>European Psychiatry</i> , 2021, 64, S161-S161.	0.1	0
153	Use of pharmacotherapies for treatment resistant depression in finland: A nationwide cohort study. <i>European Psychiatry</i> , 2021, 64, S108-S108.	0.1	0
154	Morbidity and mortality in schizophrenia with comorbid substance use disorders in Finland and Sweden. <i>European Psychiatry</i> , 2021, 64, S237-S238.	0.1	0
155	Real-world effectiveness studies of low doses of antipsychotics — Authors' reply. <i>Lancet Psychiatry</i> , 2022, 9, 536-537.	3.7	0